Nature of Event
Aurobindo Pharma Limited has disclosed the incorporation of a new wholly owned subsidiary through its existing stepdown subsidiary. The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the regulations.
Subsidiary Information
- New Entity: PT Auro Pharm Indonesia
- Incorporation Date: July 1, 2026
- Approval Received: July 9, 2026
- Country of Incorporation: Indonesia
- Ownership Structure: Wholly owned by PT Aurogen Pharma Indonesia (which is a wholly owned stepdown subsidiary of Aurobindo Pharma Limited)
- Percentage of Shareholding: 100%
Financial Details
- Initial Capital Subscription: IDR 20,000,000,000
- Share Structure: 2000 equity shares of IDR 10,000,000 each
- Consideration Type: 100% cash subscription to share capital
- Transaction Nature: Arms-length transaction with no interested parties
Business Purpose
- Industry: Pharmaceuticals
- Objective: To undertake manufacturing operations in Indonesia
- Business Alignment: The new subsidiary's activities align with Aurobindo Pharma's main line of business
Regulatory Aspects
- Governmental/Regulatory Approvals: No approvals required for the incorporation
- Timeframe for Completion: Not applicable (already incorporated)
- Historical Financials: Not available as this is a newly incorporated company
Additional Information
- The document was submitted to both National Stock Exchange of India Limited and BSE Limited
- The complete disclosure details are provided in Annexure A attached to the main letter
#Tags: #AurobindoPharma #SEBIRegulation30 #SubsidiaryIncorporation #InternationalExpansion #PharmaceuticalManufacturing